Print PDF
Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily
February 16, 2010

Teva recently agreed to  settle its long-running patent litigation with Novartis over the herpes drug Famvir (famciclovir)  by making a one-time payment to Novartis. Teva will also continue to pay royalties on U.S. sales of the generic version of Famvir. This payment covers damages from Teva’s at-risk launch of Famvir in September of 2007.

Because  Teva's launch was at-risk, and because Teva has now been forced to settle with Novartis  by paying royalties on is past and future sales, Chad Landmon, Partner at Axinn, tells The Pink Sheet that this settlement may very well curtail some at-risk launches .  Specifically, Landmon said that the Famvir settlement "may lead generic companies to question more thoroughly the decision to launch at risk.”

The article, entitled “Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis,” was published by The Pink Sheet on February 16, 2010.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.